Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23846666 | 0.88 | KMT2A (0.53) | ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL23833733 | 0.82 | POLB (0.54) | ALDH1A1KMT2AMEN1SLC22A12SMN1; SMN2 | |
| SCHEMBL23847024 | 0.78 | GAA (0.57) | ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL25754820 | 0.76 | KMT2A (0.51) | ALDH1A1USP2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL25754782 | 0.75 | FFAR4 (0.53) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPK1 | |
| SCHEMBL8941696 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4EUSP2KMT2AMEN1 | |
| SCHEMBL25754779 | 0.74 | MEN1 (0.80) | ALDH1A1KMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL23847019 | 0.73 | MEN1 (0.61) | ALDH1A1KMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL25754523 | 0.73 | KMT2A (0.47) | ALDH1A1KMT2AMEN1SLC22A12SMN1; SMN2 | |
| SCHEMBL2411993 | 0.72 | TSHR (0.46) | ALDH1A1KDM4EKMT2ASLC22A12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | ALDH1A1 2569/4885KDM4E 4448/4885USP2 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.